Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | CLK1 | P49759 | 6/20 | 0.52 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.45 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.45 |
| ▸ | CLK2 | P49760 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30474831 | 1.00 | LMNA (0.63) | LMNAMEN1KMT2ARAB9AL3MBTL1 | |
| SCHEMBL29445391 | 0.87 | HDAC1 (0.60) | LMNAMEN1KMT2ARAB9AL3MBTL1 | |
| SCHEMBL497904 | 0.87 | HDAC1 (0.60) | LMNAMEN1KMT2ARAB9AL3MBTL1 | |
| SCHEMBL2947888 | 0.84 | LMNA (0.60) | LMNAMEN1KMT2ARAB9AL3MBTL1 | |
| SCHEMBL19951048 | 0.84 | LMNA (0.59) | LMNAMEN1KMT2ARAB9AL3MBTL1 | |
| SCHEMBL3470329 | 0.83 | LMNA (0.58) | LMNAMEN1KMT2ARAB9AL3MBTL1 | |
| SCHEMBL700588 | 0.83 | LMNA (0.66) | LMNAMEN1KMT2ARAB9AL3MBTL1 | |
| SCHEMBL29481855 | 0.83 | LMNA (0.66) | LMNAMEN1KMT2ARAB9AL3MBTL1 | |
| SCHEMBL31108990 | 0.82 | MEN1 (0.64) | MEN1KMT2ARAB9AMAPTCLK1 | |
| SCHEMBL2895953 | 0.82 | MEN1 (0.64) | MEN1KMT2ARAB9AMAPTCLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 182 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590062-B2 | PD-1/PD-L1 inhibitors | GILEAD SCIENCES, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| EP-4680247-A1 | DPP1 INHIBITORS WITH POLYCYCLIC LINKERS AND USES THEREOF | Insmed Incorporated (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20250136570-A1 | HDAC INHIBITORS AND THERAPEUTIC USE THEREOF | TANGO THERAPEUTICS, INC. | 2025-05-01 | — | — | US | disclosed |
| EP-3227270-B1 | HETEROCYCLIC DERIVATIVES AND USE THEREOF | C&C RES LAB (KR) | 2024-11-13 | — | — | EP | disclosed |
| CN-118878461-A | PD-1/PD-L1 inhibitors | 吉利德科学公司 | 2024-11-01 | — | — | CN | disclosed |
| EP-4441033-A1 | NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF | Tango Therapeutics, Inc. (US) | 2024-10-09 | — | — | EP | disclosed |
| CN-118715206-A | Novel HDAC inhibitors and therapeutic uses thereof | 探戈医药股份有限公司 | 2024-09-27 | — | — | CN | disclosed |
| WO-2024192416-A1 | DPP1 INHIBITORS WITH POLYCYCLIC LINKERS AND USES THEREOF | INSMED INCORPORATED (US) | 2024-09-19 | — | — | WO | disclosed |
| CN-118598868-A | GPR52 modulator compound | 江苏海洋大学 | 2024-09-06 | — | — | CN | disclosed |
| US-12043607-B2 | HDAC inhibitors and therapeutic use thereof | TANGO THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| WO-2005030705-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE, INC. (CA) | 2005-04-07 | — | — | WO | disclosed |
| WO-2005030704-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE, INC. (CA) | 2005-04-07 | — | — | WO | disclosed |
| US-20040192681-A1 | N-acylsulfonamide apoptosis promoters | ABBVIE INC. | 2004-09-30 | — | — | US | disclosed |
| US-6720338-B2 | BCL-X1 INHIBITING COMPOSITIONS AND METHODS OF PROMOTING APOPTOSIS IN A MAMMAL | ABBOTT LABORATORIES | 2004-04-13 | — | — | US | disclosed |
| EP-1318978-A2 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | Abbott Laboratories (US) | 2003-06-18 | — | — | EP | disclosed |
| US-20020086887-A1 | N-Acylsulfonamide apoptosis promoters | ABBVIE INC. | 2002-07-04 | — | — | US | disclosed |
| US-20020055631-A1 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES | 2002-05-09 | — | — | US | disclosed |
| WO-2002024636-A2 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2002-03-28 | — | — | WO | disclosed |
| US-5340833-A | Antiarthritic, antiinflammatory, antitumor agents | EISAI CO., LTD. (JP) | 1994-08-23 | — | — | US | disclosed |
| EP-0568289-A2 | Benzothiophenes and thienothiophenes and related compounds useful, for example, as urokinase inhibitors | Eisai Co., Ltd. (JP) | 1993-11-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020086887-A1 | N-Acylsulfonamide apoptosis promoters | BAX, BCLAF1, BCL2 | LMNA 472/4885MEN1 4542/4885KMT2A 2902/4885 |
| US-20020055631-A1 | N-acylsulfonamide apoptosis promoters | BAX, BCLAF1, BCL2 | LMNA 456/4885MEN1 4627/4885KMT2A 2895/4885 |
| US-20040192681-A1 | N-acylsulfonamide apoptosis promoters | BAX, BCLAF1, BCL2 | LMNA 472/4885MEN1 4542/4885KMT2A 2902/4885 |
| US-20250136570-A1 | HDAC INHIBITORS AND THERAPEUTIC USE THEREOF | HDAC1, HDAC7, HDAC5 | LMNA 776/4885MEN1 3551/4885KMT2A 97/4885 |
| US-12590062-B2 | PD-1/PD-L1 inhibitors | CD274, PDCD1LG2, PDCD1 | LMNA 1139/4885MEN1 3035/4885KMT2A 1216/4885 |
| US-12043607-B2 | HDAC inhibitors and therapeutic use thereof | HDAC1, HDAC7, HDAC5 | LMNA 776/4885MEN1 3551/4885KMT2A 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.